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Ptrial Fibrillation and Risk of Clinical
vents in Chronic Heart Failure With and
ithout Left Ventricular Systolic Dysfunction
esults From the Candesartan in Heart failure-Assessment
f Reduction in Mortality and morbidity (CHARM) Program
ars G. Olsson, MB,* Karl Swedberg, MD, PHD, FACC,* Anique Ducharme, MD, MSC,†
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OBJECTIVES We assessed the risk of adverse cardiovascular (CV) outcomes associated with atrial
fibrillation (AF) in the Candesartan in Heart failure-Assessment of Reduction in Mortality
and morbidity (CHARM) program, which enrolled patients with chronic heart failure (CHF)
and a broad range of ejection fractions (EFs).
BACKGROUND Atrial fibrillation is associated with an increased risk of adverse CV outcomes in patients with
CHF and reduced EF. The risk of AF in patients with CHF and preserved left ventricular
ejection fraction (PEF) is unknown.
METHODS A total of 7,599 patients with symptomatic CHF were randomized to candesartan or placebo.
Patients were divided by baseline EF (40% or40%) in low or preserved EF groups. Major
outcomes were cardiovascular death or hospitalization for worsening heart failure, and
all-cause mortality. Median follow-up was 37.7 months.
RESULTS A total of 670 (17%) patients in the low EF group and 478 (19%) in the PEF group had AF
at baseline. Atrial fibrillation predicted a high risk of cardiovascular morbidity and mortality
regardless of baseline EF. Patients with AF and low EF had the highest absolute risk for
adverse CV outcomes. However, AF was associated with greater relative increased risk of the
major outcomes in patients with PEF than in patients with low EF: hazard ratio 1.72 (95%
confidence interval [CI] 1.45 to 2.06) versus 1.29 (95% CI 1.14 to 1.46), respectively. The
same was true for the risk of all-cause mortality. Candesartan was associated with similar
treatment effects regardless of baseline rhythm.
CONCLUSIONS Atrial fibrillation is associated with an increased risk of CV outcomes in patients with CHF
and either reduced EF or PEF. Candesartan improved outcomes similarly regardless of
baseline rhythm. (J Am Coll Cardiol 2006;47:1997–2004) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.060College of Cardiology Foundation
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wtrial fibrillation (AF) is the most common sustained
rrhythmia in patients with chronic heart failure (CHF) (1).
ts prevalence and incidence increase with age and with
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4, 2005, accepted January 2, 2006.everity of heart failure, rising up to 50% in some studies (2).
oss of atrial contraction leads to reduced stroke volume,
levated filling pressures, and atrial dilatation. The rapid
entricular rate and its irregularity further impairs cardiac
lling and emptying (3–4). The prognostic importance of
F occurring in CHF has been analyzed in various settings,
ncluding clinical trials (5–8), outpatient cohorts (9–12),
nd within epidemiologic studies (13). These studies have
ainly evaluated the risks related to AF in patients with
educed left ventricular systolic function.
A preserved left ventricular ejection fraction (PEF) may be
resent in up to 50% of patients with heart failure (14). Cohort
tudies of heart failure patients who were hospitalized (15–17),
he Italian Network for Chronic Heart Failure (IN-CHF)
egistry (18) and the echocardiographic substudy of the Euro-
eart Failure Survey (19) have shown that AF is at least as
ommon in patients with heart failure and PEF as in those
ith reduced EF. Little is known, however, about the prog-
ostic impact of AF in patients with heart failure and PEF.
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Atrial Fibrillation in Chronic Heart Failure May 16, 2006:1997–2004The Candesartan in Heart failure-Assessment of Reduc-
ion in Mortality and morbidity (CHARM) program as-
essed the effect of candesartan across a broad spectrum of
atients with symptomatic heart failure, including those
ith PEF (20). The objective of the present analysis was
o evaluate the risk related to AF according to baseline
jection fraction (EF) using the prespecified clinical
utcomes. The risk in patients developing AF during
ollow-up was also assessed.
ETHODS
he design of the CHARM program has been described in
etail earlier (21). In brief, 7,601 patients (7,599 with data)
ith symptomatic CHF in New York Heart Association
unctional class II to IV were randomized to candesartan
target dose 32 mg once daily, mean dose 24 mg) or
atching placebo. Patients were divided into one of the
hree component trials based on left ventricular ejection
raction (LVEF) and treatment with an angiotensin-
onverting enzyme inhibitor (ACE-I). The CHARM-
lternative study included patients with EF 0.40 not
reated with ACE-I because of intolerance. The CHARM-
dded study included patients with LVEF 0.40 already
reated with an ACE-I, and the CHARM-Preserved study
valuated patients with LVEF 0.40 regardless of ACE-I
reatment. Patients in CHARM-Preserved had to have had
hospital admission for a cardiac reason at some time in the
ast. Major exclusion criteria included serum creatinine
265 mol/l (3 mg/dl), serum potassium 5.5 mmol/l
5.5 mEq/l), and symptomatic hypotension. The investi-
ator was asked to complete a structured electrocardiogram
ECG) report at the randomization visit. Follow-up visits
ere scheduled two, four, and six weeks and six months
Abbreviations and Acronyms
ACE-I  angiotensin-converting enzyme inhibitor
AF  atrial fibrillation
CHARM  Candesartan in Heart failure-Assessment of
Reduction in Mortality and morbidity
CHF  chronic heart failure
COMET  Carvedilol Or Metoprolol European Trial
CV  cardiovascular
DIG  Digitalis Investigation Group
ECG  electrocardiogram
EF  ejection fraction
HR  hazard ratio
IN-CHF  Italian Network for Chronic Heart Failure
LIFE  Losartan Intervention for End Point
Reduction in Hypertension trial
LVEF  left ventricular ejection fraction
OR  odds ratio
PEF  preserved left ventricular ejection fraction
PRIME II  Second Prospective Ibopamine Evaluation
trial
SOLVD  Studies Of Left Ventricular Dysfunction
Val-HeFT  Valsartan Heart Failure Trialfter randomization and every 4 months thereafter until the gnd of the study. At the end of follow-up, investigators were
sked to report whether or not a new diagnosis of AF had
een made during follow-up. In the present analysis, during
he median follow-up of 37.7 months, all patients with new
evelopment of AF were included regardless of whether the
pisodes were symptomatic or whether they were paroxys-
al or persistent.
nalysis. The primary objective of this analysis was to
xamine the risk of cardiovascular (CV) events related to
aseline AF according to baseline EF. We also assessed
he frequency of CV events in patients in whom new AF
eveloped during follow-up. These were prespecified
nalyses, but the data on new development of AF were
ollected without relationship to the timing of new-onset
F. In secondary analyses, we examined the influence of
aseline rhythm (AF or other) on the effect of candesar-
an on outcomes and on the need for permanent with-
rawal from study drug because of serious adverse effects
uch as hypotension, hyperkalemia, or increased serum
reatinine level. Patients were classified as having AF or
o AF according to the investigator interpretation of
heir baseline ECG. Patients in sinus rhythm at baseline
ut with a history of AF were categorized as no AF.
nalyses were carried out for all patients or with patients
ivided by EF. The CHARM-Added and CHARM-
lternative participants were considered the low EF
roup and CHARM-Preserved participants were consid-
red the PEF group. The primary outcome of the
omponent trials in the CHARM program was the
omposite of CV death or unplanned admission to the
ospital for the management of worsening CHF, and
hese events were adjudicated by a blinded committee.
respecified secondary outcomes included all-cause mor-
ality, CV death, admission to the hospital for CHF, and
atal or nonfatal stroke. We classified all deaths as CV
nless an unequivocal non-CV cause was established.
tatistical analysis. All outcome variables were defined as
he time to an event or censoring and were analyzed with
he proportional hazards model. Both simple Cox regression
odels and multiple Cox regression models were fitted to
ata. The explanatory variables included in the multiple
egression models were the same set of 33 variables that
ere adjusted for in the CHARM program (20), except for
he variable ACE-I at baseline. All subgroups analyzed for
he low EF group were stratified by component trial
CHARM-Added or CHARM-Alternative). When an
nalysis included new-onset AF as an explanatory variable,
logistic regression model was fitted to data because
nformation on timing of occurrence of AF was lacking, and
hese analyses are therefore presented as odds ratios rather
han hazard ratios (HR). In this analysis, the response was
onsidered to be a binary variable, indicating whether or not
patient experienced a CV event. All p values were
enerated from the Wald test statistics.
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May 16, 2006:1997–2004 Atrial Fibrillation in Chronic Heart FailureESULTS
aseline characteristics. A total of 7,601 patients were
andomized to candesartan or placebo, 7,599 with available
ata. Baseline characteristics are summarized in Table 1. In
eneral, patients with AF were older, had a higher baseline
eart rate, and more often had a cardiothoracic ratio of0.5
nd a history of hospitalization for heart failure. Patients
ith AF less frequently had a history of prior myocardial
nfarction, angina pectoris, or diabetes mellitus. Ischemic
able 1. Baseline Demographics
Variable Low
AF
670
ge (yrs) 68.1 (9.9)
BP (mm Hg) 76.5 (10.9)
BP (mm Hg) 127.3 (18.1)
R (beats/min) 76.5 (15.6)
MI 27.7 (5.0)
jection fraction 0.29 (0.08)
ardiothoracic ratio 0.5 231 (34.5%)
ale gender 523 (78.1%)
urrent smoker 81 (12.1%)
YHA functional class
II 193 (28.8%)
III 439 (65.5%)
IV 38 (5.7%)
reatinine 2.0 mg/dl 16 (9.3%)
edical history
Previous CHF hospitalization 539 (80.4%)
Previous MI 294 (43.9%)
Angina pectoris 293 (43.7%)
Stroke 73 (10.9%)
Hypertension 346 (51.6%)
Diabetes mellitus 178 (26.6%)
CABG 143 (21.3%)
PCI 57 (8.5%)
Implantable cardiac defibrillator 21 (3.1%)
Pacemaker implanted 82 (12.2%)
tiology
Ischemic heart disease 341 (50.9%)
Idiopathic dilated cardiomyopathy 191 (28.5%)
Hypertension 63 (9.4%)
Atrial fibrillation 22 (3.3%)
CG findings at baseline
Bundle branch block 181 (27.0%)
Paced rhythm 64 (9.6%)
Left ventricular hypertrophy 64 (9.6%)
oncomitant medication
Digitalis glycoside 533 (79.6%)
Diuretics 632 (94.3%)
Spironolactone 171 (25.5%)
Beta-blocker 332 (49.6%)
Calcium channel blocker 86 (12.8%)
Antiarrhythmic agent 100 (14.9%)
Lipid-lowering drug 184 (27.5%)
Oral anticoagulant 513 (76.6%)
Acetylsalicylic acid 179 (26.7%)
ACE inhibitors 397 (59.3%)
CE angiotensin-converting enzyme; AF atrial fibrillation; BMI body mass in
lood pressure; ECG  echocardiographic; EF  ejection fraction; HR  heart rate;
oronary intervention; SBP  systolic blood pressure.eart disease was the most common etiology of heart failure megardless of presence or absence of AF, but it was a less
ommon cause in patients with AF (43.5%) than without
F (64.8%). Hypertension was reported as the etiology of
F more commonly in patients with AF, much more
ommonly in patients with PEF, and most commonly in
hose with AF and PEF. Patients with AF had similar EF
o those in sinus rhythm but had a worse New York Heart
ssociation functional classification and were more likely to
ave had a pacemaker implanted. Patients with AF were
Preserved EF
No AF AF No AF
3,906 478 2,545
64.7 (11.1) 71.4 (9.6) 66.4 (11.1)
75.7 (10.7) 78.4 (11.1) 77.8 (10.6)
127.4 (18.9) 134.3 (18.6) 136.5 (18.4)
73.5 (12.8) 76.6 (14.5) 70.3 (11.8)
27.6 (5.1) 28.9 (5.9) 29.2 (5.8)
0.29 (0.08) 0.55 (0.09) 0.54 (0.09)
942 (24.1%) 133 (27.8%) 361 (14.2%)
2,865 (73.3%) 277 (57.9%) 1,534 (60.3%)
624 (16.0%) 57 (11.9%) 352 (13.8%)
1,387 (35.5%) 269 (56.3%) 1,567 (61.6%)
2,406 (61.6%) 197 (41.2%) 943 (37.1%)
113 (2.9%) 12 (2.5%) 35 (1.4%)
86 (6.1%) 6 (4.5%) 46 (4.8%)
2,811 (72.0%) 390 (81.6%) 1,686 (66.3%)
2,370 (60.7%) 115 (24.1%) 1,225 (48.1%)
2,242 (57.4%) 187 (39.1%) 1,630 (64.0%)
322 (8.2%) 48 (10.0%) 220 (8.6%)
1,897 (48.6%) 294 (61.5%) 1,649 (64.8%)
1,128 (28.9%) 108 (22.6%) 749 (29.4%)
994 (25.4%) 59 (12.3%) 595 (23.4%)
645 (16.5%) 31 (6.5%) 495 (19.4%)
147 (3.8%) 4 (0.8%) 19 (0.7%)
334 (8.6%) 45 (9.4%) 176 (6.9%)
2,634 (67.4%) 158 (33.1%) 1,548 (60.8%)
873 (22.4%) 52 (10.9%) 211 (8.3%)
234 (6.0%) 133 (27.8%) 551 (21.7%)
10 (0.3%) 81 (16.9%) 53 (2.1%)
1,196 (30.8%) 78 (16.3%) 356 (14.1%)
259 (6.7%) 31 (6.5%) 125 (4.9%)
632 (16.3%) 86 (18%) 358 (14%)
1,879 (48.1%) 313 (65.5%) 529 (20.8%)
3,395 (86.9%) 430 (90.0%) 1,829 (71.9%)
749 (19.2%) 87 (18.2%) 265 (10.4%)
2,187 (56.0%) 216 (45.2%) 1,468 (57.7%)
512 (13.1%) 136 (28.5%) 808 (31.7%)
493 (12.6%) 47 (9.8%) 253 (9.9%)
1,707 (43.7%) 112 (23.4%) 1,150 (45.2%)
1,077 (27.6%) 350 (73.2%) 398 (15.6%)
2,305 (59.0%) 107 (22.4%) 1,655 (65.0%)
2,152 (55.1%) 77 (16.1%) 499 (19.6%)
ABG coronary artery bypass graft; CHF chronic heart failure; DBP diastolic
myocardial infarction; NYHA  New York Heart Association; PCI  percutaneousEF
dex; Core often treated with digitalis, diuretic agents, and oral
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Atrial Fibrillation in Chronic Heart Failure May 16, 2006:1997–2004nticoagulants and less often with beta-blocker and
cetylsalicylic acid. A small number of patients were
reated with an antiarrhythmic drug in either group,
egardless of AF, with more frequent use in patients with
low EF.
utcomes by baseline AF. Atrial fibrillation recorded on
aseline ECG was associated with an increased risk of
orbidity and mortality (Figs. 1 to 3). Patients with AF and
ow EF had the highest absolute risk for adverse CV
utcomes (e.g., 45% with CV death or CHF hospitaliza-
ion) relative to those with low EF and sinus rhythm (37%
Figure 1. Risk of baseline atrial fibrillation (AF) for cardiovascular (CVigure 2. Time to cardiovascular (CV) death or hospitalization because of heart
eft ventricular ejection fraction.ith an event), PEF and AF (34% with an event), or PEF
nd sinus rhythm (21% with an event) (Figs. 1 to 3).
owever, AF was associated with a greater increase in the
isk of CV death or hospitalization for worsening heart
ailure in patients with PEF (HR 1.72, 95% confidence
nterval [CI] 1.45 to 2.06) than in patients with low EF,
HR 1.29, 95% CI 1.14 to 1.46, p for interaction 0.008).
he same was true for all-cause mortality: PEF HR 1.80
95% CI 1.46 to 2.21) and low EF HR 1.38 (95% CI 1.21
o 1.59, p for interaction 0.041). Similarly, for each of these
dverse CV outcomes, with the exception of stroke, patients
ts depending on ejection fraction (EF). CHF  chronic heart failure.failure. AF  atrial fibrillation; EF  ejection fraction; PEF  preserved
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May 16, 2006:1997–2004 Atrial Fibrillation in Chronic Heart Failureith low EF and AF at baseline had the highest absolute
isk, and patients with PEF and AF at baseline had a greater
ncrease in risk than those with low EF and AF. When
djusted for 32 covariates in multiple regression analysis,
aseline AF remained an independent risk factor for CV
eath or hospitalization for heart failure in patients with
EF (HR 1.32, 95% CI 1.06 to 1.65, p  0.015) but not in
hose with low EF (HR 1.12, 95% CI 0.97 to 1.29, p 
.12). After covariate adjustment, AF at baseline remained
n independent predictor of all-cause mortality regardless of
aseline EF: PEF HR 1.37 (95% CI 1.06 to 1.79) and low
F HR 1.22 (95% CI 1.04 to 1.43).
utcomes in patients with new-onset AF. In 392 pa-
ients, AF developed during follow-up, 263 (7.8%) in the
ow EF group and 129 (4.9%) in the PEF group. Patients
ith new-onset AF experienced a higher risk of morbidity
nd mortality regardless of baseline EF. The odds ratio for
V death or hospitalization for worsening heart failure was
.22 (95% CI 2.90 to 6.13) in the PEF group and 3.17 (95%
I 2.45 to 4.09) in the low EF group; p  0.19 for
nteraction. For all-cause mortality the odds ratio was 2.57
95% CI 1.70 to 3.90) in the PEF group and 1.85 (95% CI
.44 to 2.37) in the low EF group; p  0.18 for interaction.
gain, the absolute risk of an adverse CV outcome was
ighest in the low EF-new AF patient group, but the
atients with PEF and new AF had a greater relative
ncrease in risk than those with low EF and new AF (Fig.
). For example, the absolute risk of CV death or CHF
ospitalization was 66% in the low EF-new AF group and
as increased from 20% to 47% by the new development of
F in the PEF group (Fig. 4).
reatment effects. In the CHARM-Overall program,
andesartan reduced the risk of the composite primary end
oint in both AF (HR 0.83, 95% CI 0.69 to 0.99) and
igure 3. Time to all-cause mortality. AF  atrial fibrillation; CI  confid
raction.on-AF groups (HR 0.84, 95% CI 0.77 to 0.92; p for cnteraction 0.80). There were also trends toward a reduced
isk of all-cause mortality in both groups that did not reach
tatistical significance, HR 0.82 (95% CI 0.67 to 1.01) for
F and HR 0.94 (95% CI 0.85 to 1.04) for no AF, p for
nteraction 0.22 (Fig. 5). In the PEF group there was no
ignificant effect of candesartan on the primary composite
nd point in the overall population and no difference in
ffect according to presence or absence of AF (p for
nteraction 0.82). In patients with low EF, candesartan
educed CV morbidity and mortality to a similar degree
egardless of the presence of AF at baseline (Table 2).
dverse effects. Patients with baseline AF had higher
iscontinuation rates than those without because of hypo-
ension (3.4% vs. 2.5%), increased creatinine (6.3% vs.
.3%), and hyperkalemia (1.8% vs. 1.3%), respectively.
ISCUSSION
his analysis from the CHARM program shows that
aseline AF is associated with an increased risk of morbidity
nd mortality in patients with symptomatic heart failure
egardless of baseline EF and that the increase in risk
ttributable to AF is even higher in patients with PEF. The
ncreased risk of stroke was similar between the two
roups. Development of new AF during follow-up was
ssociated with an increased risk of CV mortality or
ospitalization for heart failure, all-cause mortality, and
atal or nonfatal stroke. The main difference from previ-
us analyses is that our present analysis involved a broad
pectrum of heart failure patients, including those with
EF, treated with contemporary heart failure and other
V medications. This broad perspective affords the
pportunity to make an important observation regarding
rognosis that previously has not been possible. Specifi-
interval; EF  ejection fraction; PEF  preserved left ventricular ejectionally, in patients with CHF and PEF, the presence or
n
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Atrial Fibrillation in Chronic Heart Failure May 16, 2006:1997–2004ew development of AF is associated with such a sub-
tantial increase in risk for adverse CV outcomes that it
uts patients at absolute risk levels that are nearly as high
s those for patients with CHF and low EF who remain
n sinus rhythm.
aseline characteristics. Patients with AF were in general
lder, had a worse functional class, and had more enlarged
earts despite EF similar to patients with no AF. Several
linical trials, outpatient cohorts, and epidemiologic studies
ave shown a mutual relationship between the two condi-
Figure 4. Risk of new-onset atrial fibrillation (AF) for cardiovascular (Cigure 5. Treatment effects depending on baseline heart rhythm in CHARM
ardiovascular.ions in which heart failure begets AF (13,22) and AF
egets CHF (13,23). In 9,193 patients with hypertension
nd left ventricular hypertrophy, new-onset AF was associ-
ted with a five-fold increase in hospitalizations for CHF
24). Beta-blockers were less often used in patients with
F, which could reflect the higher age and more co-
orbidity. Treatment with digitalis was more frequent
mong AF patients, but higher baseline heart rates
uggest that single-drug therapy may be insufficient for
dequate rate control (25). Around 75% of patients with
ents depending on ejection fraction (EF). CHF  chronic heart failure.-Overall. AF  atrial fibrillation; CHF  chronic heart failure; CV 
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May 16, 2006:1997–2004 Atrial Fibrillation in Chronic Heart FailureF were treated with oral anticoagulants regardless of
aseline EF. This is higher than reported from the
uroHeart Failure Survey (26).
utcomes. Our analysis extends previous findings by
howing that AF, whether present at baseline or of new
nset, is an independent risk factor for adverse CV out-
omes in patients with heart failure regardless of baseline
F. After adjustment for baseline factors, there are still
ifferences in risk increase associated with AF between
atients with low EF and PEF. The reason for the differ-
nce is unclear, but the presence of AF may reflect different
tages of CHF between the two patient groups. Although
atients with a low EF are at a higher absolute risk for CV
vents than those with PEF (Figs. 1 to 4) (27), the added
isk of AF is particularly important for patients with PEF.
atients with PEF might have a lower tolerability for
ncontrolled ventricular rate, thus being more prone to
eteriorate (3,4).
arlier studies. To this date, we are aware of only one trial
ublished in full evaluating the prognostic impact of su-
raventricular tachycardia (including AF) in heart failure
atients with evidence of preserved systolic function and
linical evidence of heart failure. The DIG trial included
88 patients with LVEF 0.45 and clinical signs of heart
ailure in an ancillary study, and these patients were ana-
yzed for incidence of supraventricular tachycardia together
ith patients in the main trial. The development of su-
raventricular tachycardia during the study was indepen-
ently associated with a higher risk of mortality and stroke
egardless of baseline EF (28).
In the previous literature there is conflicting evidence
bout the prognostic importance of AF. Four of five trials
ith follow-up started before 1990 showed an independent
elationship between AF and mortality: one was an epide-
iologic study (13); one included patients in the SOLVD
rial, in which AF also predicted CV morbidity (6); and two
ere in severe heart failure (9,10). One (12) of five
7,8,10,11) trials with follow-up starting in 1990 or later
howed an independent relationship between AF and mor-
ality. That was an unselected cohort of 944 elderly patients
ospitalized for heart failure. AF did not predict 1-month
able 2. Treatment Effects in Patients With Low EF Depending
Candesarta
Events
ardiovascular death or hospitalization because of
heart failure
AF 139/336 (4
No AF 678/1,953 (3
ll-cause mortality
AF 109/336 (3
No AF 533/1,953 (2
V death or CHF hospitalization or nonfatal stroke
AF 147/336 (4
No AF 705/1,953 (3
F  atrial fibrillation; CHF  chronic heart failure; CI  confidence interval; CVehospitalization. The other substantial recent analysis was tf the 3,029 patients randomized to either carvedilol or
etoprolol tartrate and followed up for 5 years within the
OMET study (8). The AF did not independently predict
ll-cause mortality, but did predict all-cause mortality or
ospitalization and CV death or hospitalization for heart
ailure. Of note, in trials with follow-up started in 1990 or
ater, patients were almost universally treated with ACE-I
nd the use of class I antiarrhythmic drugs had decreased
onsiderably.
Four of five published analyses of new-onset AF showed
prognostic relationship with mortality, one an analysis from
he Framingham study (13). and three analyses from the DIG,
OMET, and Val-HeFT clinical studies (8,28,29). The
xception was a small group of patients with severe CHF
nrolled in the PRIME II study (7).
ngiotensin II receptor blockers in patients with heart
ailure and AF. This is the first trial to evaluate the effect
f an angiotensin II receptor blocker on CV outcomes in
atients with CHF and concomitant AF, and moreover,
ver a broad range of EF. In Val-HeFT study, valsartan
educed the incidence of AF in patients with reduced EF
29). In a recent analysis of the CHARM program, we
ave shown that candesartan reduces the risk of devel-
ping AF in patients with both reduced and preserved EF
30). The patients enrolled in the CHARM-Preserved
omponent trial, which had symptomatic CHF and PEF,
ad some similarities to those in the LIFE trial, in which
osartan was superior to atenolol in reducing a composite
nd point of CV death, stroke, or myocardial infarction
n 342 patients with hypertension, left ventricular hyper-
rophy, and AF despite similar decreases in blood pres-
ure (31).
tudy limitations. The primary analysis of this study was
ased on the diagnosis of AF using the baseline ECG.
ew-onset AF was documented at the end of the study
rom investigator reports and not by systematic recordings,
o episodes of AF may have been missed, particularly
aroxysmal AF. Also, patients who died early did not have
he opportunity to develop AF, so collectively the relation-
hip reported here probably underestimates the true rela-
ionship of new-onset AF and mortality. The relationship in
Heart Rhythm
Placebo Events HR 95% CI Interaction
160/334 (48%) 0.78 0.62–0.98 0.62
784/1,953 (40%) 0.82 0.74–0.91
139/334 (42%) 0.70 0.55–0.90 0.05
569/1,953 (29%) 0.92 0.82–1.04
166/334 (50%) 0.80 0.64–1.00 0.58
799/1,953 (41%) 0.84 0.76–0.93
rdiovascular; EF  ejection fraction; HR  hazard ratio.on
n
1%)
5%)
2%)
8%)
4%)
6%)ime between an adverse CV outcome and new-onset AF
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hen onset of AF occurred. However, our findings are
upported by the fact that three previous randomized trials
ncluding 15,000 patients have shown that new-onset
upraventricular tachycardia or AF are strong predictors of
ortality in time-dependent analyses.
onclusions. Atrial fibrillation is associated with an in-
reased risk of adverse CV outcomes in patients with CHF
nd either reduced or preserved left ventricular systolic
unction. Patients with AF and reduced EF have the highest
bsolute risk, and those with AF and PEF have a greater
ncrease in risk. New-onset AF is also associated with an
ncreased risk with or without left ventricular systolic
ysfunction. Candesartan improved clinical outcomes re-
ardless of baseline rhythm.
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